Core B. Clinical Translational Core

项目摘要-临床翻译核心 本申请寻求资金，以继续智力与发展研究所 加州大学戴维斯分校残疾研究中心(IDDRC)。IDDRC成立于2013年 是该网络14个国际数据中心中最新的一个。临床翻译核心(CTC)旨在建立 并维护一个最适合招募、诊断评估、神经行为 不同临床疾病的表型特征和潜在生物学机制的映射 人口。反恐委员会将处理五个具体目标。目标1是加强招聘各种不同类型的 参与者。这一目标将通过系统的社区参与和不断增长的参与者注册来实现 这包括多个民族、种族和经济背景，既有非典型人群，也有典型人群 年龄跨度很大。目标2是提供人类参与者的行为和诊断特征。 这一目标将通过向有经验的临床医生提供机会来实现，他们可以进行专门的评估， 为最佳实践研究提供建议，提供标准化措施管理方面的培训，建立初步 可靠性和监控管理保真度，以及通过提供访问专门的测试空间和 将研究人员与临床试验专业知识联系起来。目标3是提供对最先进的“深度”的访问 基因组学中的“表型”工具和专业知识。这一目标将通过提供工具和培训来实现，以增强 参与者的表型特征，使最新的深表型和 向IDDRC调查人员提供基因组学知识。目标4是支持将技术融入研究，特别是 远程医疗方法，可导致可扩展的、可获得的、经济高效的IDD疾病治疗。 这一目标将通过提供现场高级研究IT支持和访问完整的 加州大学戴维斯分校的技术和专业知识。目标5是促进生物有机质的收集和分析 来自人类参与者的信息，并促进国际发展研究中心项目之间的共享。这一目标将通过提供 静脉采血服务以及使用核心管理的冷冻库进行生物样品储存的准入和奖励措施 以及指向Mind IDDRC生物和分子分析核心以及Mind Institute基因组的链接 医学计划。与上一个供资期间相比，拟议的反恐委员会已大大扩大， 其中最显著的变化是深层表型和测量传播的整合 以前的神经行为分析核心的功能，这导致我们将这个扩展的核心重命名为 CTCx。反恐委员会主任是萨利·奥佐诺夫博士。

PROJECT SUMMARY – CLINICAL TRANSLATIONAL CORE The present application seeks funding to continue the MIND Institute Intellectual and Developmental Disabilities Research Center (IDDRC) at the University of California, Davis. The IDDRC was launched in 2013 and is the newest of the 14 IDDRCs in the network. The Clinical Translational Core (CTC) is designed to establish and maintain an operational framework that is optimal for recruitment, diagnostic assessment, neurobehavioral characterization, and mapping of phenotypes to underlying biological mechanisms for a diverse range of clinical populations. The CTC will address five specific aims. Aim 1 is to enhance recruitment of a diverse range of participants. This aim will be met through systematic community engagement and a growing participant registry that includes multiple ethnicities, races, and economic backgrounds with both atypical and typical populations across a wide age span. Aim 2 is to provide behavioral and diagnostic characterization of human participants. This aim will be met by providing access to experienced clinicians who can conduct specialized evaluations, advise studies in best practices, provide training in administration of standardized measures, establish initial reliability, and monitor administration fidelity, as well as by providing access to specialized testing space and connect investigators with clinical trials expertise. Aim 3 is to provide access to state-of-the-art “deep phenotyping” tools and expertise in genomics. This aim will be met by offering tools and training to enhance phenotypic characterization of participants, making available recent innovations in deep phenotyping and genomics to IDDRC investigators. Aim 4 is to support the integration of technology into research, especially telehealth methodologies that can lead to scalable, accessible, and cost-effective treatments for IDD conditions. This aim will be met by providing on-site high-level research IT support and access to the full array of technologies and expertise at UC Davis Health. Aim 5 is to facilitate collection and analysis of biospecimens from human participants and promote sharing across IDDRC projects. This aim will be met by providing phlebotomy services and access and incentives to use a core-managed freezer library for biospecimen storage as well as by links to the MIND IDDRC Biological and Molecular Analysis Core and the MIND Institute Genomic Medicine Program. The proposed CTC has been significantly expanded relative to the previous funding period, with the most significant change being the integration of the deep phenotyping and measure dissemination functions of the previous Neurobehavioral Analysis Core, which has led us to rename this expanded core, the CTCx. The Director of the CTC is Sally Ozonoff, PhD.